Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
After approval for AD REV is $20B per year, expenses 50%, PE=20. So $AVXL=$2597
Says who?
After approval AVXL PRICE IS AT LEAST $2597!
Actually, when we see that P3 AD TLD is good, you can easily expect to see an AVXL sp above $1249.
You know that any sp for AVXL after approval will be
above $500.
P3 AD TLD will occur as scheduled as early as September 21 2022, first day of Fall! Don’t listen to all the lies!
Sell no stock before it’s time. AVXL prices now are are extremely diminished. P3 AD TLD will deliver the very best results! Expect much much higher!
Always lookin at your watch.
Warren doesn’t wear one!
They are all traders! Longs are long!
Eventual $1249 sp for AVXL is real!
AVXL is going down until it just won’t! Traders do that. When revenue comes watch out!
The AVXL stock is unaffected in the end by market movement. Only trader heads count that. The solid therapy for AD that ANAVEX has will yield robust revenue streams of approximately $30B per year just for its US business. Everyone knows this!
Your confused!
Should see the GOAT of all short squeezes.
Just indicates unusual manipulation, as usual.
Why do you call it OPEN LABEL, if you expect it to be LOCKED?
EARLY ALZHEIMER’S P3 TRIAL THUMBNAIL
NCT03790709
509 PATIENTS, 3 COHORTS OF 169:HIGH, MED, PLACEBO DOSE.
First posted Jan 2, 2019
Last updated July 14, 2022
Study start July 3, 2018
ACTUAL STUDY COMPLETION JUNE 30, 2022
Primary Measures (Two, 48 week each patient)
1. ADAS-Cog - Alzheimers Disease Assessment Scale for Cognition
2. ADCS-ADL - Activities of Daily Living.
Two secondaries plus Five additional measures.
TRIAL was conducted in 54 separate locations in 5 countries.
Country state number
Australia New South Wales 5
Queensland 1
South 1
Victoria 8
Western 1
Canada Alberta 1
British Columbia 2
Nova Scotia 2
Ontario 5
Germany 8
Netherlands 3
Untied Kingdom 16
I agree. Like RedShoulders posts!
You know that whatever gets said on this board is totally no account. Additionally it does not matter if anyone on this board understands any of this science of ANAVEX. It might be best if no one even tries to understand! I don’t think anyone does! That Missling understands is sufficient, just listen to him.
Just leave, sell everything, don’t come back and buy all the SAVA you can! You will be in heaven. You are going to the Center of the ALZHEIMER UNIVERSE. You will get ALZHEIMERS and keep it forever. You may only lose a little A-Beta. Stay with SAVA!
S1R without expression is like a fire truck with flat tires and no gasoline.
S1R when needed should be expressed which allows it to be useful, but still does nothing.
S1R can be ACTIVATED by A 2-73 after a need causes the receptor to be available by being expressed.
Expression is a gatekeeping function, but ACTIVATION is what does the fixing.
Celebrate the 30 years of A-Beta failed medicine! Invest in SAVA! Get an FDA approved shot of ADUHELM to explode your brain!
They really don’t have any interest in A-Beta AD meds like SAVAs cause they don’t work. That stock is pumped with fake sell to self transactions. Papier-mâché stock SAVA. Try BIIBs ADUHELM to get brain bleed and swelling, approved for that!
Invest in a real startup like ANAVEX that has real drugs A 2-73 that will be shown to work by cellular homeostasis. Buy AVXL!
No worries here! ANAVEX A 2-73 works by boosting cellular homeostasis. Go to SAVA if you just want A-Beta killer stuff! Go to Biogen ADUHELM to get your brain to explode and bleed!
Hey POS-guy! Dr. Missling is perfection. Go post your crap on SAVA board. If you just want A-Beta only stuff and trade talk. Notice yesterday this board talks real AD results!
so DONT SELL. Sit tight with your shares, so you can sell 2 shares at $40, 10 shares at $110, 1000 shares at $1000, and 1000 shares at $1249. Then you can really let loose with selling 10000 shares at $10000.00.!
Yes, more than nice, it’s confirmatory of the results we have seen. Phase 2a AD super responders have prevailed over 6 years on A 2-73.
This is going to speed up a little as time goes on! No one wants to delay this!
Unlikely. Too late. More like Sept 21, 2022 in the beginning of Fall after he had the data for up to 3 maybe 4 months!
Well before Nov. Dr M says Fall.
A lot of people are going to live longer taking A 2-73 and A 3-71 drugs from ANAVEX!
It ain’t a piddling $30 stock price!
The a priori probability measure given stat sig figure as calculated is independent of the sample size N! In simple language the stat sig number is stat sig or not no matter what the value of N!
You announcing whether anything is stat sig is total crap! Also it has been contradicted by authorities in ANAVEX!
Take note of geographical distribution that’s very diverse. Also difficult to manage the data, which takes more time.
EARLY ALZHEIMER’S P3 TRIAL THUMBNAIL
NCT03790709
509 PATIENTS, 3 COHORTS OF 169:HIGH, MED, PLACEBO DOSE.
First posted Jan 2, 2019
Last updated July 14, 2022
Study start July 3, 2018
ACTUAL STUDY COMPLETION JUNE 30, 2022
Primary Measures (Two, 48 week each patient)
1. ADAS-Cog - Alzheimers Disease Assessment Scale for Cognition
2. ADCS-ADL - Activities of Daily Living.
Two secondaries plus Five additional measures.
TRIAL was conducted in 54 separate locations in 5 countries.
Country state number
Australia New South Wales 5
Queensland 1
South 1
Victoria 8
Western 1
Canada Alberta 1
British Columbia 2
Nova Scotia 2
Ontario 5
Germany 8
Netherlands 3
Untied Kingdom 16
Just a wild claim with no support and a huge bias against DR MISSLING.
I think the best that ANAVEX can hope for with the P3 AD data of 509 patients is total and absolute approval. Anything less is a disappointment!
Timing the market and its results is a foolish game. In the long run, true data prevails. Play the long term, sleep nights and win!
Missling always produces fantastic results. He never has failed!
100s of $BILLIONS
Keep in mind that ALZHEIMER’s has about 70% overlap with PARKINSON’s DISEASE DIMENTIA! So any ifs will be very lower case, because PDD results were Stellar and so were P2a AD results!